Investment Rating - The report maintains a "Buy" rating for the following companies: 罗博特科 (300757.SZ), 唯科科技 (301196.SZ), 能科科技 (603859.SH), and 合合信息 (688615.SH) [9][62]. Core Insights - The REDSearcher framework has achieved a breakthrough in deep search agent technology, overcoming three major industry bottlenecks and setting a new standard in the field [3][20][29]. - OpenAI's GPT-5.4 has been released, marking a new era for intelligent agents with its native computer operation capabilities, significantly enhancing its performance across various tasks [4][33][34]. - The AI financing landscape remains active, with significant investments in the CPO sector and brain-computer interface companies, indicating strong market confidence [48][51]. Summary by Sections Computing Power Dynamics - The REDSearcher team launched a low-cost, scalable deep search agent training framework, achieving state-of-the-art results with a 30B parameter model, surpassing several well-known closed-source models [3][20][29]. - The rental prices for computing power remain stable, with specific pricing details for various configurations provided [20][21]. AI Application Dynamics - Bing's weekly traffic increased by 2.70%, while ChatGPT and Gemini also showed significant traffic figures, indicating a competitive landscape in AI applications [31][32]. - GPT-5.4 is the first general model to possess native computer operation capabilities, allowing it to perform complex tasks typically handled by humans [33][34]. AI Financing Trends - AyarLabs completed a $500 million E round financing, reaching a valuation of $3.75 billion, while NVIDIA invested $2 billion each in Lumentum and Coherent to enhance its AI infrastructure [48][50]. - Science Corporation raised $230 million in C round financing, achieving a valuation of $1.5 billion, focusing on the commercialization of its retinal implant technology [51][52]. Investment Recommendations - Broadcom reported a strong Q1 2026 performance with revenues of $19.311 billion, driven by a 106% year-on-year growth in AI business revenue, reinforcing the positive outlook for AI infrastructure investments [5][60]. - The report suggests focusing on companies with high growth potential in the AI sector, including 唯科科技, 合合信息, 能科科技, and 罗博特科 [61].

Investment Rating - The investment rating for the semiconductor industry is maintained as "Buy" for specific companies such as SMIC and Haiguang Information, while Huahong is not rated [2][7]. Core Insights - The semiconductor industry is experiencing a structural increase in prosperity driven by strong demand for AI computing power, leading to significant price increases across the supply chain, with price hikes ranging from 10% to 80% [3]. - The AI Agent era is redefining the value of CPUs, which are now critical for AI responsiveness and cost efficiency, resulting in a shortage of CPUs in the market [4]. - The report highlights a divergence in the industry's recovery, with leading companies like Baiwei Storage seeing substantial profit increases, while many chip companies continue to struggle with losses [3]. Industry Dynamics - The semiconductor sector is witnessing a price surge due to AI infrastructure demands, with the global AI chip market expected to grow from $11 billion in 2019 to $72.6 billion by 2025 [3]. - The semiconductor index showed a decline of 5.57% during the week of March 2-6, 2026, indicating a volatile market environment [13]. - The semiconductor materials sector experienced the largest decline of 8.97%, while the digital chip design sector saw the smallest decline of 4.52% during the same period [16]. Company Focus and Earnings Forecast - Key companies to watch include SMIC, Huahong, Tian Shu Zhi Xin, Haiguang Information, and Xinyuan [5]. - SMIC's earnings per share (EPS) is projected to increase from 0.46 in 2024 to 0.77 in 2026, with a price-to-earnings (PE) ratio decreasing from 231.52 to 137.76 [7]. - Tian Shu Zhi Xin is expected to improve its EPS from -5.89 in 2024 to -1.78 in 2026, with a significant negative PE ratio [7]. Global Semiconductor Sales - Global semiconductor sales reached $82.54 billion in January 2026, marking a 46.1% year-on-year increase, with China contributing $22.82 billion [35]. - The sales of semiconductor equipment in China reached $14.56 billion in Q3 2025, reflecting a 12.61% year-on-year growth [39]. NAND Flash Market Insights - The NAND Flash market is projected to see a revenue increase of 23.8% in Q4 2025, driven by AI infrastructure demands and a shortage of mechanical hard drives [63]. - Major NAND manufacturers are expected to maintain high prices due to supply-demand imbalances, with price increases projected at 85% to 90% in Q1 2026 [65].

Investment Rating - The report maintains a "Recommended" investment rating for the aluminum industry due to supply disruptions caused by geopolitical conflicts in the Middle East [11]. Core Views - Geopolitical tensions are causing disturbances in aluminum supply, which is expected to lead to a continued rise in aluminum prices [6][11]. - The copper market is experiencing tight supply conditions, supporting a positive outlook for copper prices [11]. - The report highlights that the gold industry is also rated as "Recommended" due to the Federal Reserve entering a rate-cutting cycle [11]. Summary by Sections Industry Performance - The non-ferrous metals sector (Shenwan) has shown a performance increase of 2.4% over the last month, 29.6% over the last three months, and 105.2% over the last year, outperforming the CSI 300 index [3]. Price and Inventory Data - Aluminum prices in China are reported at 24,410 CNY/ton, reflecting an increase of 1,060 CNY/ton from the previous week [8]. - LME aluminum inventory decreased by 8,675 tons, while domestic SHFE inventory increased by 38,512 tons [8]. - Copper prices have seen a decline, with LME copper closing at 12,840 USD/ton, down 642 USD/ton from the previous week [6]. Supply and Demand Dynamics - The report notes that the operating rate for domestic copper rod production has increased significantly to 62.47%, up 44.09 percentage points [8]. - The report indicates that the geopolitical situation has led to supply disruptions, particularly affecting aluminum production in Qatar and Bahrain [9]. Recommended Stocks - The report recommends several stocks across different sectors: - Gold: Zhongjin Gold, Shandong Gold, Chifeng Gold, Shandong International, China National Gold International [12]. - Copper: Zijin Mining, Luoyang Molybdenum, Jincheng Mining, Western Mining, Cangge Mining, Wukuang Resources [12]. - Aluminum: Shenhuo Co., Yunnan Aluminum, Tianshan Aluminum, China Hongqiao [12]. - Tin: Xiyang Co., Huaxi Nonferrous [12]. - Antimony: Hunan Gold, Huaxi Nonferrous [12].

2026 年 03 月 09 日 海外滞胀交易升温，A 股防御为主 分析师：杨芹芹 S1050523040001 yangqq@cfsc.com.cn 分析师：孙航 S1050525050001 sunhang@cfsc.com.cn 联系人：卫正 S1050124080020 weizheng2@cfsc.com.cn 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 25 (%) 沪深300 相关研究 1、《假期海外资产上涨，国内消费 出行量增，把握春季红包的两大方 向》2026-02-24 2、《海外等待波动下降，A 股春节 红包可期》2026-02-10 3、《ETF 流出风险整体可控，A 股 延续震荡上行》2026-01-26 投资要点 ▌ 海外宏观热点与策略 海外宏观： 1）美以伊局势不确定性升温，VIX 飙升至关税以 来新高。2）霍尔木兹海峡停摆+产油国减产，原油创史上最 大周涨幅，重塑资产定价逻辑。3）非农爆冷，类滞胀交易升 温。4）私人信贷遭遇流动性冲击，但因规模有限且有多种缓 冲工具，整体风险可控，不至于次贷再现。 美股：短期仍保持谨慎。地 ...

Investment Rating - The report maintains a "Recommended" rating for the humanoid robot industry, indicating a positive outlook for the sector [2][6]. Core Insights - The humanoid robot industry is experiencing significant growth, with a projected 28% increase in industrial robot production by 2025, and over 300 humanoid robot models launched by Chinese companies, accounting for more than half of the global total [3][4]. - The Chinese government is actively supporting the development of the humanoid robot industry, emphasizing the importance of original innovation and key technology breakthroughs during the "Two Sessions" [4]. - Tesla's Cortex 2 supercomputer is set to enhance the training capabilities for its Optimus robot, indicating a strong commitment to advancing AI and robotics technology [3]. Summary by Sections Humanoid Robot Sector - The Huaxin humanoid robot index fell by 6.55% this week, but has a cumulative return of 99.6% since 2025 [18]. - The sector's trading volume accounted for 13.9% of the CSI 2000 index, indicating a relatively high level of market activity [18]. - Among the sub-sectors, the reducer segment performed relatively well, while other components like dexterous hands and screws saw declines [21]. Automotive Sector - The CITIC automotive index decreased by 2.6%, underperforming the broader market [34]. - The commercial vehicle index showed better performance compared to passenger vehicles and other segments [35]. - Key companies such as Changyuan Donggu and Feilong shares saw significant gains, while others like Daimai and Tianpu shares experienced notable declines [40]. Key Companies and Profit Forecasts - Recommended companies include: - Mould Technology (EPS forecast: 0.68 in 2024, PE: 18.88) [11] - Shuanglin Co. (EPS forecast: 1.24 in 2024, PE: 26.81) [11] - New Spring Co. (EPS forecast: 2.00 in 2024, PE: 39.76) [11] - The report highlights the importance of components such as joints, screws, and motors in the humanoid robot sector, recommending specific companies for investment [10].

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of March 9, 2026 [1]. Core Insights - The report highlights a strong trend in China's innovative pharmaceuticals going global, with 39 license-out transactions recorded by mid-February 2026, totaling approximately $29.53 billion in upfront payments and over $49 billion in total deal value [2]. - Despite the positive outlook for innovative drug exports, the innovative drug index has declined by 4.84% as of March 4, 2026, underperforming the CSI 300 index by 4.25 percentage points, indicating a divergence between market sentiment and fundamentals [2]. - The report emphasizes the importance of clinical data validation and milestone payments in the upcoming phase for innovative drugs, particularly following the surge in outbound licensing activities [2]. Summary by Sections 1. Market Trends - The report notes that the pharmaceutical retail market in China saw a retail scale of 588 billion yuan in December 2025, marking a 4.3% year-on-year growth, although the overall annual growth rate was slightly negative at -0.57% [7]. - The report indicates that the average transaction price in retail pharmacies decreased by 6% in 2025, influenced by a decline in the purchase frequency of consumer goods like health products [7]. 2. Supply Chain Dynamics - The report discusses the impact of macroeconomic changes on the supply side, noting that 90% of monitored chemical products experienced price increases as of March 6, 2026, with the chemical products price index rising by 14.1% since the beginning of the year [3]. - It highlights that the pricing strategy in the raw material drug sector is crucial for long-term development, especially in light of rising upstream costs [3]. 3. Regulatory Environment - The report mentions the management of dual-use items, which has led to significant price discrepancies between domestic and international markets, potentially benefiting domestic medical product manufacturers [4]. - It also notes that the regulatory environment is becoming stricter, particularly for key materials, which could enhance the competitive advantage of domestic products [4]. 4. Innovative Drug Development - The report highlights the emergence of oral GLP-1 drugs, with significant sales growth for Eli Lilly's products, and notes that Chinese companies are actively pursuing GLP-1 research and development [5]. - It emphasizes the ongoing collaborations in the small nucleic acid field, with several significant partnerships and acquisitions taking place in early 2026 [6]. 5. Stock Recommendations - The report recommends specific companies based on various trends, including raw material drug cycles, dual-use item management, and advancements in small nucleic acids [10]. - Companies such as Yuyuan Pharmaceutical, Sunshine Nuohuo, and Yifeng Pharmacy are highlighted for their potential in the current market environment [10].

双融日报 --鑫融讯 2026 年 03 月 09 日 ▌ 热点主题追踪 今日热点主题：银行、电网设备、煤化工 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：62 分（较热） 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 25 (%) 沪深300 相关研究 | 1、《双融日报》2026-03-06 | | --- | | 2、《双融日报》2026-03-05 | 3、《双融日报》2026-03-04 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 62 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1 1、银行主题：近期资金风险偏好下降，银行板块具备低估 值、高股息（半数标的股息率超 4.5%）的"稳健锚"属性。 在经济增速放缓和市场波动加大时，银行股凭借稳定的分红 能力，成为险资、社保等长期资金的重要配置标的。相关标 的：农业银行（601288）、宁波银行（002142） 2、电网设备主题：全球 AI 数据中心（AIDC）耗电量巨大， 催生了对高功率、高稳 ...

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The report highlights the rapid growth of China's innovative pharmaceuticals, with 39 license-out transactions and upfront payments totaling approximately $2.953 billion, indicating a strong trend in international collaboration [2] - Despite the positive outlook for innovative drugs, the innovative drug index has declined by 4.84%, underperforming the CSI 300 index by 4.25 percentage points, suggesting a disconnect between market sentiment and fundamentals [2] - The report emphasizes the importance of clinical data validation and milestone payments in the upcoming phase for China's innovative pharmaceuticals, particularly after a period of market anticipation [2] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry index has recently underperformed, ranking 17th among 31 primary industry indices with a decline of 2.78% [21][23] - The industry has seen a monthly decline of 3.09%, underperforming the CSI 300 index by 3.45 percentage points [24][42] 2. Supply-side Macro Background Changes - The report notes that the prices of upstream chemical products have generally increased due to various policies, with 90% of monitored products experiencing price hikes [3] - Specific raw materials like vitamins and amino acids have begun to see price increases, indicating a shift in the pricing cycle [3] 3. Dual-use Item Management - The management of dual-use items is expected to create significant price differences between domestic and international markets, potentially benefiting domestic medical products [4] 4. GLP-1 Oral Era - The report discusses the significant market share increase of GLP-1 drugs, with Eli Lilly's sales reaching $36.5 billion in 2025, and the introduction of oral GLP-1 medications expected to change the market dynamics [5] 5. Small Nucleic Acid Field - The report highlights ongoing mergers and collaborations in the small nucleic acid sector, with significant financial commitments from companies for innovative therapies [6] 6. Retail Drug Market - The retail drug market in China showed a positive trend in Q4 2025, with a total retail scale of 616.5 billion yuan, although the annual growth rate remained slightly negative at -0.57% [7] 7. Focus on Oral Immunomodulatory Drugs - The report emphasizes the potential of oral immunomodulatory drugs, particularly in treating psoriasis, with promising clinical trial results for new candidates [8] 8. Stock Recommendations - The report provides specific stock recommendations based on various trends, including raw material cycles, dual-use item management, and advancements in small nucleic acids and oral immunomodulatory drugs [10][12]

Investment Rating - The report maintains a "Buy" rating for the media industry, indicating a positive outlook for investment opportunities in this sector [1]. Core Insights - The media sector is positioned to benefit from the dual attributes of technology application and domestic demand, particularly in the context of the government's economic development goals for 2026, which aim for a growth rate of 4.5% to 5% [3][14]. - The transition to Web4.0 is expected to enhance the media landscape through AI empowerment, leading to new applications and content production paradigms [3][15]. - The report highlights the emergence of new consumption patterns, such as the "reward economy" and "accompaniment economy," which are anticipated to drive demand for media products and services [19][20]. Summary by Sections 1. Industry Review - The media industry has shown varied performance, with the internet marketing index experiencing significant declines while other sectors like vocational education have fared better [13]. - The report notes a substantial increase in the popularity of female-oriented AI dramas, which have become a key growth area within the industry [31][32]. 2. Industry Dynamics - The gaming sector continues to thrive, with major players like Tencent and NetEase leading in revenue generation, particularly during festive periods [27]. - E-commerce platforms are innovating with AI technologies, enhancing user engagement and operational efficiency [29][30]. - The report emphasizes the growing importance of AI in content creation, particularly in the realm of female-centric narratives, which are gaining traction in the market [31][32]. 3. Recommended Stocks - The report identifies several stocks to watch, including: - Shunwang Technology (300113) benefiting from Web4.0 applications - Mango Super Media (300413) focusing on AI-driven content - Wanda Film (002739) expected to recover post-holiday adjustments [4][8]. 4. Profit Forecasts - The report provides earnings per share (EPS) and price-to-earnings (PE) ratios for various companies, indicating a generally optimistic outlook for the media sector [8].

Core Conclusions - The report emphasizes the need to focus on geopolitical uncertainties, tariffs, and liquidity disturbances while awaiting volatility to stabilize. Domestically, attention is directed towards the government work report and the 14th Five-Year Plan, with a continuous verification of economic recovery, particularly in social financing and prices. The A-share market is expected to experience oscillating rotations, with a balanced style, focusing on defensive, cyclical price increases, and structural opportunities in technology themes [4][31]. A-share Strategy - March is identified as a critical verification period for policies and the economy, with a focus on new insights from the Two Sessions and ongoing verification of economic recovery. Key signals from the Two Sessions include: 1) a growth target range of 4.5%-5% with an emphasis on quality and price; 2) the launch of major projects and new policy financial tools to support the year; 3) initiatives for increasing residents' income and enhancing social security to promote consumption and domestic demand; 4) optimizing existing resources and fostering new growth drivers [5][7]. - The report outlines a calendar effect for the Two Sessions, indicating a pattern of pre-meeting increases, mid-meeting adjustments, and post-meeting recoveries, with styles shifting from stability to financial, growth, and consumer sectors [5][25]. Industry Selection - Three main structural opportunities are highlighted: 1) Defensive sectors (high dividend stocks, oil and petrochemicals, public utilities, agriculture, forestry, animal husbandry, and fishery); 2) Cyclical price increases (coal, steel, chemicals, non-ferrous metals); 3) Technology themes (AI, commercial aerospace, future energy, quantum technology, and embodied intelligence) [5][29][43]. - The report notes that the performance of the A-share market is influenced by external geopolitical uncertainties and domestic policy support, leading to a balanced growth and value style, with opportunities remaining in small and mid-cap stocks after adjustments [42][37]. Economic Window - March marks the beginning of a verification period for economic recovery, with a focus on financial data, exports, retail sales, real estate, infrastructure, and price data. Key attention is on whether financial data from February can continue to improve and the extent of demand recovery in exports, retail sales, and real estate [9][10]. Valuation Insights - The report indicates that the overall valuation of the A-share market has reached a new high in the current bull market, with a PE-TTM of 23.74 as of March 1, 2026, still having a 3% upside potential compared to the previous bull market peak of 24.47 [15][16]. Liquidity Trends - Public and wealth management products have shown significant growth at the beginning of the year, with a notable increase in new issuances and net subscriptions, indicating a strong influx of funds into the market. The report anticipates that the trend of residents moving deposits into wealth management products will continue [20][23].